Optiver Holding
KROS icon

Optiver Holding’s Keros Therapeutics KROS Stock Holding History

Optiver Holding’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92K Buy
273
+16
+6% +$178 ﹤0.01% 2182
2026
Q1 		$2.84K Buy
257
+88
+52% +$1.36K ﹤0.01% 1695
2025
Q4 		$3.44K Sell
169
-43
-20% -$754 ﹤0.01% 1656
2025
Q3 		$3.35K Buy
+212
New +$3.13K ﹤0.01% 2104

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Optiver Holding's KROS Position: Q2 2026 in Review

Optiver Holding increased its Keros Therapeutics (KROS) stake by 6.2% in Q2 2026, buying an estimated $178 and bringing the position to 273 shares worth $2.92K. The position accounts for ﹤0.01% of the portfolio, ranked #2182.

Optiver Holding first reported a position in KROS in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.44K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Optiver Holding held 273 shares of Keros Therapeutics worth $2.92K as of Q2 2026.
  • Optiver Holding bought 16 Keros Therapeutics shares in Q2 2026, an estimated $178.
  • Keros Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2182 holding.
  • Optiver Holding first reported a position in Keros Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Keros Therapeutics position peaked at $3.44K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.